Founded on June 1, 1960 in Vršac, Hemofarm A.D. today it is the leading generic pharmaceutical company in Serbia and the region.
The primary activity of the company is the production of quality, efficient, safe and affordable pharmaceutical products. Since 2006, Hemofarm has been part of the German STADA group, one of the world's largest generic pharmaceutical companies.
Hemofarm is a leader on the Serbian pharmaceutical market. Occupying more than 70% of the total export of pharmaceutical products from the country, the Vršac company is also the largest Serbian exporter of medicines. It produces more than 5.5 billion tablets and capsules a year. It operates on three continents and has a team of about 3,000 employees. In addition to the fact that it is present in 36 markets around the world, Hemofarm is also one of the largest pharmaceutical manufacturers in this region.
The company is committed to constant innovation. In addition to researching and developing modern pharmaceutical products, Hemofarm pays special attention to sustainable business. It is in line with the BSCI Code of Social Responsibility and respect for human rights. 97.6% compliance with BSCI is the best result among all companies operating in Serbia.
In addition to its headquarters in Vršac, Hemofarm has registered offices in Belgrade, Niš, Novi Sad and Kragujevac. The headquarters of the subsidiary is in Šabac, which became part of Hemofarm AD with the acquisition in January 2015.
In addition to Serbia, Hemofarm also has subsidiaries in the region: in Macedonia, Bosnia and Herzegovina, Montenegro, and Romania. In addition to the subsidiary, Hemofarm's European laboratory is located in Timisoara, Romania.